zigakibart

Phase 3Small molecule

zigakibart is one of 3 small molecule programs targeting Immunoglobulin A Nephropathy (IgAN). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immunoglobulin a Nephropathy (igan)Recruiting

Kidney DiseasesRecruiting

Immunoglobulin a Nephropathy (igan)Phase 2

Recruiting

Kidney DiseasesPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Immunoglobulin a Nephropathy (igan)

#DrugCompanyPhaseTrials

Telitacicept

VVor Biopharma

Phase 2

1 2

zigakibart

Novartis

Phase 3

1 3

ADX-038

AADARx Pharmaceuticals, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Recruiting

Immunoglobulin a Nephropathy (igan)

NCT07146906

Q2 2031

Phase 3Recruiting

Kidney Diseases

NCT06858319

Clinical

Trials by Indication[1]

Kidney Diseases1 trial

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.

Recruiting· Novartis logo

Novartis·Phase 3·NCT06858319·220 enrolled

Immunoglobulin A Nephropathy (IgAN)1 trial

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

Recruiting· Novartis logo

Novartis·Phase 2·NCT07146906·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for zigakibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zigakibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zigakibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

zigakibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Q2 2031

Trials by Indication[1]

Kidney Diseases1 trial

Immunoglobulin A Nephropathy (IgAN)1 trial

References

Drug Info

Quick Facts

Related News